EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apelin‐13 Attenuates Blood–Brain Barrier Dysfunction Following Intracerebral Hemorrhage via Targeting the Keap1/Nrf2 Signaling

Pingping Guo, Rabeea Siddique, Juanfeng Qian, Lingxiao Qi, V Wee Yong, Mengzhou Xue iD

CNS Neuroscience & Therapeutics · 2025-12 · 31 (12)

DOI: 10.1002/cns.70706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 29.12.2025. Verfasst von Pingping Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Blood-Brain Barrier, NF-E2-Related Factor 2, Cerebral Hemorrhage, Kelch-Like ECH-Associated Protein 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood–brain barrier (BBB) dysfunction serves as a critical driver of the secondary brain injury following intracerebral hemorrhage (ICH). Previous research has indicated that Apelin‐13 demonstrates the potential to alleviate BBB dysfunction in various cerebrovascular disorders. However, the precise mechanisms through which Apelin‐13 preserves BBB integrity remain elusive. This study investigated whether Apelin‐13 exerted neuroprotective effects by targeting the Keap1/Nrf2 signaling.

Methods

An in vivo ICH model was established using collagenase. Neurological function, brain edema, tight junction protein levels, and Evans blue leakage were assessed. In vitro, bEnd.3 monolayers were induced by hemin to simulate ICH conditions. To assess the role of Apelin‐13 in the Keap1/Nrf2 signaling, we employed specific shRNAs targeting Nrf2 and apelin receptor (APJ). The neuroprotective effects of Apelin‐13 in hemin‐stimulated bEnd.3 cells were assessed through transendothelial electrical resistance assay, western blotting, and immunofluorescence analysis.

Results

Apelin‐13 treatment significantly mitigated brain damage, reduced cerebral edema, and promoted neurological recovery in ICH mice. These effects were accompanied by a significant decrease in matrix metalloproteinase‐9 expression and an increase in tight junction protein levels. Similar protective effects were observed in hemin‐induced bEnd.3 cells, where Apelin‐13 additionally promoted Nrf2 expression and suppressed Keap1 expression, suggesting the involvement of the Keap1/Nrf2 signaling. Critically, APJ silencing blocked the effects of Apelin‐13 on the Keap1/Nrf2 pathway. Furthermore, Nrf2 knockdown eliminated the protective effects of Apelin‐13, reversing its attenuation of apoptosis, preservation of tight junction integrity, and reduction of oxidative stress in hemin‐stimulated bEnd.3 cells.

Conclusions

In conclusion, these findings demonstrate that through its engagement with APJ, Apelin‐13 activates the endothelial Keap1/Nrf2 pathway to protect against ICH‐induced BBB disruption and facilitate neurological recovery, highlighting its therapeutic promise for ICH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierNF-E2-Related Factor 2Cerebral HemorrhageKelch-Like ECH-Associated Protein 1Intercellular Signaling Peptides and ProteinsNeuroprotective AgentsAnimalsSignal TransductionMiceMaleMice, Inbred C57BLBrain EdemaDisease Models, Animal

Stichwörter der Autor:innen

Apelin‐13Keap1/Nrf2blood–brain barrierintracerebral hemorrhageoxidative stress

Substanzen

NF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseapelin-13 peptideKeap1 protein, mouseIntercellular Signaling Peptides and ProteinsNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan, China.
  • Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Mengzhou Xue

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, P., Siddique, R., Qian, J., Qi, L., Yong, V. W., & Xue, M. (2025). Apelin‐13 Attenuates Blood–Brain Barrier Dysfunction Following Intracerebral Hemorrhage via Targeting the Keap1/Nrf2 Signaling. CNS Neuroscience & Therapeutics, 31(12). https://doi.org/10.1002/cns.70706

Vancouver

Guo P, Siddique R, Qian J, Qi L, Yong VW, Xue M. Apelin‐13 Attenuates Blood–Brain Barrier Dysfunction Following Intracerebral Hemorrhage via Targeting the Keap1/Nrf2 Signaling. CNS Neuroscience & Therapeutics. 2025;31(12). doi:10.1002/cns.70706

BibTeX
@article{Guo2025,
  author = {Guo, Pingping and Siddique, Rabeea and Qian, Juanfeng and Qi, Lingxiao and Yong, V Wee and Xue, Mengzhou},
  title = {Apelin‐13 Attenuates Blood–Brain Barrier Dysfunction Following Intracerebral Hemorrhage via Targeting the Keap1/Nrf2 Signaling},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  volume = {31},
  number = {12},
  doi = {10.1002/cns.70706}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche